<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281798</url>
  </required_header>
  <id_info>
    <org_study_id>16-008556</org_study_id>
    <nct_id>NCT03281798</nct_id>
  </id_info>
  <brief_title>Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO)</brief_title>
  <acronym>LUTO</acronym>
  <official_title>Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO): A Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodrigo Ruano M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate the safety, feasibility and effectiveness of fetal&#xD;
      cystoscopy in the prenatal diagnosis and therapy of fetuses with bladder outlet obstruction.&#xD;
      Fetal bladder outlet obstruction is a rare congenital anomaly with severe consequences to the&#xD;
      fetus. Because of the bladder outlet obstruction, amniotic fluid is diminished, drastically&#xD;
      leading to abnormal development of the fetal lungs. In addition, the obstruction leads to&#xD;
      significant kidney damage, including development of end stage renal disease. Fetal&#xD;
      vesicoamniotic shunting is the clinical therapeutic option for these fetuses. However, the&#xD;
      shunt has many complications including blockage and dislodgement. Fetal cystoscopy has been&#xD;
      proposed as an alternative treatment with potential advantages over the shunt by allowing the&#xD;
      correct prenatal diagnosis and specific treatment. Initial clinical trials have demonstrated&#xD;
      favorable outcomes.&#xD;
&#xD;
      The purpose of the study is to study the outcomes of maternal and fetal patients who are&#xD;
      undergoing fetal intervention for severe, isolated lower urinary tract obstruction (LUTO) at&#xD;
      Mayo Clinic in Rochester, Minnesota. The objectives are to evaluate the safety, feasibility,&#xD;
      and effectiveness of fetal cystoscopy as an experimental procedure in avoiding perinatal&#xD;
      death and renal impairment and to compare to our clinical experience with fetal&#xD;
      vesico-amniotic shunting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of successfully completed surgical procedures</measure>
    <time_frame>Four hours following start of surgical procedure</time_frame>
    <description>Performance of percutaneous fetal cystoscopy with ultrasound-fetoscopic guidance</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Congenital Disorders</condition>
  <condition>Bilateral Hydronephrosis</condition>
  <condition>Lower Urinary Tract Obstructive Syndrome</condition>
  <arm_group>
    <arm_group_label>Fetuses with LUTO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performance of ultrasound-guided, percutaneous fetal cystoscopy with the Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set</intervention_name>
    <description>2.0 mm fetoscopy or flexible ureteroscope</description>
    <arm_group_label>Fetuses with LUTO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant females age ≥ 18 years&#xD;
&#xD;
          -  Oligohydramnios or Anhydramnios&#xD;
&#xD;
          -  Singleton male fetus with LUTO, dilated bladder, &quot;keyhole sign&quot; and bilateral&#xD;
             hydronephrosis&#xD;
&#xD;
          -  Urine analysis: urinary sodium &lt; 100 milliequivalents per liter (mEq/L), chloride &lt; 90&#xD;
             mEq/L, osmolarity &lt;200 milliosmoles/liter (mOsm/L) and β2-microglobulin &lt;6mg/L&#xD;
&#xD;
          -  Absence of chromosomal abnormalities and associated anomalies&#xD;
&#xD;
          -  Gestational age at the time of the procedure between 16 0/7 weeks and 25 6/7 weeks&#xD;
&#xD;
          -  Normal karyotype by invasive testing (amniocentesis or CVS).&#xD;
&#xD;
          -  Family have considered and declined the option of termination of the pregnancy at less&#xD;
             than 24 weeks.&#xD;
&#xD;
          -  Family has sufficient social support and ability to understand requirements of the&#xD;
             study.&#xD;
&#xD;
          -  Parents or guardians are willing to provide signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fetal anomaly or congenital cardiac anomaly unrelated to LUTO&#xD;
&#xD;
          -  Female fetus&#xD;
&#xD;
          -  Increased risk for preterm labor, cervical length (&lt;1.5 cm), previous preterm birth,&#xD;
             history of incompetent cervix with or without cerclage&#xD;
&#xD;
          -  Placental abnormalities (previa, abruption, accreta) known at time of enrollment&#xD;
&#xD;
          -  Contraindications to surgery including previous hysterotomy in active uterine segment&#xD;
&#xD;
          -  Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal&#xD;
             membrane separation, uterine anomalies incompatible with fetoscopy&#xD;
&#xD;
          -  Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune&#xD;
             thrombocytopenia affecting the current pregnancy&#xD;
&#xD;
          -  Maternal HIV, Hepatitis-B, Hepatitis-C positive (testing must be done and be negative)&#xD;
&#xD;
          -  Maternal medical condition that is a contraindication to surgery or anesthesia&#xD;
&#xD;
          -  Patient does not have health insurance to cover routine prenatal clinical care,&#xD;
             including prenatal ultrasound, amniocentesis, tocolysis, admission, delivery, and&#xD;
             fetal vesico-amniotic shunting&#xD;
&#xD;
          -  Inability to comply with travel and follow-up requirements of the trial&#xD;
&#xD;
          -  Participation in another intervention study that influences maternal and fetal&#xD;
             morbidity and mortality or participation in this trial in a previous pregnancy&#xD;
&#xD;
          -  Patients declining invasive testing&#xD;
&#xD;
          -  Unable to understand the study procedures or unable to provide voluntary informed&#xD;
             consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females of child-bearing age</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Ruano, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Rodrigo Ruano M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydronephrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

